Kyoto University
Overview
Mermaid diagram (expand to render)
Kyoto University is a prestigious national university in Kyoto, Japan, founded in 1897. The university is renowned for its liberal academic tradition and has produced numerous Nobel laureates in physics, chemistry, and medicine. [@iwata2023] Kyoto University's contributions to neuroscience and neurodegenerative disease research have been particularly significant, with researchers making fundamental discoveries about protein misfolding, neural circuit function, and therapeutic approaches.
Key neuroscience and neurodegeneration research centers include: [@yamada2024]
- Institute for Frontier Life and Medical Sciences: Research on molecular mechanisms of neurodegeneration
- Graduate School of Medicine: Clinical research on neurological and psychiatric disorders
- Center for Neural Systems: Basic neuroscience research on neural circuits and behavior
- Kawaguchi Memorial Institute: Research on neurobiology and disease mechanisms
Kyoto University has made significant contributions to understanding protein misfolding diseases, particularly through studies on prion diseases, polyglutamine diseases, and alpha-synucleinopathies. The university's Research Center for Neurological Diseases conducts comprehensive research from basic science to clinical applications. [@shimizu2025]
History and Institutional Development
Founded in 1897 as the Imperial University of Kyoto, the institution has grown from a small medical school into one of Japan's premier research universities. The university's distinctive academic culture, emphasizing freedom and individual creativity, has fostered groundbreaking scientific discoveries.
Kyoto University's contributions to biomedical research accelerated after World War II, with the establishment of the Graduate School of Medicine and specialized research institutes. The development of world-class facilities and recruitment of leading scientists positioned the university at the forefront of neuroscience research in Asia.
Research Programs
Graduate School of Medicine
The Department of Neurology and Neuroscience at Kyoto University conducts comprehensive research on neurodegenerative diseases:
Alzheimer's Disease: Researchers investigate amyloid biology, [tau](/proteins/tau) pathology, and therapeutic development. Studies span from basic mechanisms to clinical translation [@mori2022].
Parkinson's Disease: [Alpha-synuclein](/proteins/alpha-synuclein) research, dopaminergic neuron biology, and clinical trials are major focus areas [@takahashi2023]. Research includes development of novel therapeutics and biomarkers.
Amyotrophic Lateral Sclerosis: Studies on [TDP-43](/proteins/tdp-43) pathology, RNA metabolism, and therapeutic targets [@ohta2023].
Prion Diseases: Prion protein research and transmissible encephalopathies remain strengths of the institution [@suzuki2024].
Center for Brain Research
The Center for Brain Research (CBR) focuses on:
- Molecular and cellular neuroscience
- Developmental neuroscience
- Neural circuit function
- Computational neuroscience
Institute for Frontier Life Medical Sciences
Research programs include:
- Stem cell biology and regenerative medicine
- iPSC technology for disease modeling [@shimizu2025]
- Gene therapy approaches [@kobayashi2023]
Key Research Areas
Protein Misfolding and Aggregation
Kyoto University has a long-standing expertise in studying protein misfolding diseases. Research encompasses:
Prion Diseases: Studies on PrPsc propagation, strain diversity, and therapeutic approaches. Japanese researchers have made seminal discoveries about prion biology and transmission.
Alpha-Synucleinopathies: Investigations of [alpha-synuclein](/proteins/alpha-synuclein) aggregation mechanisms, prion-like propagation, and therapeutic strategies [@yamada2024].
Tauopathies: Research on tau protein hyperphosphorylation, aggregation, and spread in the brain [@takahashi2024].
Polyglutamine Diseases: Studies on CAG repeat disorders including Huntington's disease and spinocerebellar ataxias.
Neurodegeneration in Animal Models
Researchers utilize multiple animal models to study disease mechanisms:
- Transgenic mouse and rat models
- C. elegans models for rapid screening
- Zebrafish for developmental studies
- Primate models for translational research
RNA Binding Proteins in Neurodegeneration
TDP-43, FUS, and other RNA-binding proteins are studied in the context of ALS and FTD [@ohta2023]. Research examines how mutations in these proteins cause disease and identifies therapeutic targets.
Neuroinflammation and Microglia
Neuroinflammatory processes are recognized as important contributors to neurodegeneration [@murayama2023]. Studies investigate:
- Microglial activation mechanisms
- Cytokine and chemokine signaling
- Therapeutic approaches to modulate inflammation [@yoshida2023]
Therapeutic Antibody Development
Kyoto researchers develop monoclonal antibodies targeting pathological proteins. Programs include:
- Anti-amyloid antibodies for AD
- Anti-alpha-synuclein antibodies for PD
- Anti-tau antibodies for tauopathies
Stem Cell and iPSC Research
Induced pluripotent stem cell technology enables patient-specific disease modeling [@shimizu2025]. Researchers generate neurons from patients with familial forms of AD, PD, and ALS to study disease mechanisms and screen therapeutics.
Dopaminergic Neuron Therapy: Cell replacement approaches for Parkinson's disease using stem cell-derived neurons [@kondo2024].
Research Themes
Tau Biology and Propagation
Kyoto University has been a leader in understanding tau protein biology [@takahashi2024]. Research includes:
- Mechanisms of tau phosphorylation
- Tau aggregation and fibril formation
- Tau propagation between neurons
- Tau-based therapeutic strategies
Alpha-Synuclein Research
Studies on [alpha-synuclein](/proteins/alpha-synuclein) span multiple aspects of PD pathogenesis [@yamada2024]:
- Aggregation mechanisms
- Membrane interactions
- Cellular clearance pathways
- Prion-like spreading
LRRK2 Kinase Biology
The LRRK2 kinase is a major therapeutic target in PD [@hattori2023]. Research addresses:
- LRRK2 signaling pathways
- Kinase inhibitor development
- Pathogenic mutations and their effects
Biomarker Development
Early diagnosis is a major research priority. Investigators develop:
- CSF biomarkers for AD and PD
- Blood-based biomarkers
- Neuroimaging markers [@nakanishi2024]
- Novel PET tracers [@nakata2024]
Mitochondrial Dysfunction
Energy metabolism impairment is a hallmark of neurodegeneration. Research examines:
- Mitochondrial respiratory chain defects
- Mitophagy and mitochondrial quality control [@tanaka2023]
- Therapeutic approaches to improve mitochondrial function
Autophagy and Protein Clearance
Cellular clearance mechanisms are impaired in neurodegenerative diseases [@fujita2023]. Studies investigate:
- Macroautophagy and mitophagy
- The ubiquitin-proteasome system
- Therapeutic enhancement of clearance
Synaptic Dysfunction
Synaptic loss is an early event in neurodegeneration [@uemura2022]. Researchers study:
- Mechanisms of synaptic degeneration
- Synaptic protein trafficking
- Therapeutic protection of synapses
Neurovascular Function
Blood-brain barrier dysfunction and vascular contributions to disease are investigated. Research examines:
- Pericyte and endothelial cell function
- Neurovascular unit integrity
- Therapeutic approaches to protect vasculature
Notable Facilities
Advanced Imaging Center
- 7 Tesla MRI for human imaging
- PET/CT and PET/MRI scanners
- Two-photon microscopy
- Super-resolution microscopy
iPSC Facility
- GMP-grade cell culture
- Differentiated neuronal populations
- Disease modeling capabilities
Animal Models
- Transgenic mouse facility
- Behavioral testing core
- Surgical suites for stereotactic injections
Genomics and Proteomics
- Next-generation sequencing
- Mass spectrometry proteomics
- Single-cell analysis platforms
International Collaborations
Kyoto University maintains extensive international partnerships:
- University of California, San Diego: Joint research programs and faculty exchanges
- University of Cambridge: Collaboration on protein aggregation research
- Max Planck Institute for Biophysics: Partnership on structural biology
- European Molecular Biology Laboratory: Scientific exchanges and joint projects
- Global Alzheimer's Association: Participation in international research consortia
Training Programs
Graduate Education
- PhD in Neuroscience
- PhD in Medical Sciences
- Combined MD/PhD programs
- Master's programs in biomedical sciences
Postdoctoral Training
- Postdoctoral positions in all research laboratories
- Training in cutting-edge technologies
- Career development programs
Clinical Training
- Neurology residency program
- Movement disorders fellowship
- Research fellowships for clinical investigators
Future Directions
Precision Medicine
Kyoto is developing personalized approaches to neurodegenerative disease treatment based on genetic and biomarker profiling.
AI Integration
Computational approaches and AI are being integrated into drug discovery and disease modeling [@tokyo2024].
Clinical Translation
Increased emphasis on translating basic discoveries into clinical applications through industry partnerships and clinical trial infrastructure.
International Leadership
The university aims to expand its role as a leading institution for neuroscience research in Asia and globally.
Major Research Initiatives
Japan Brain Project
Kyoto University plays a central role in the Japan Brain Project, a national initiative coordinating brain research across Japanese institutions. Key focus areas include:
- Brain mapping and connectomics
- Development of brain-inspired artificial intelligence
- Novel therapeutics for brain disorders
- Neurotechnology development
National Neurodegeneration Research Network
Kyoto leads a national network coordinating neurodegeneration research across Japanese universities and hospitals:
- Multi-center clinical studies for Alzheimer's and Parkinson's disease
- Shared biobank resources for biomarker development
- Collaborative preclinical research programs
- Training and career development for young investigators
Pharmaceutical Partnerships
The university maintains active pharmaceutical collaborations:
- Joint research programs with major pharmaceutical companies
- Clinical trial design and execution partnerships
- Drug discovery and validation collaborations
- Biomarker development partnerships
Clinical Research Infrastructure
Affiliated Hospitals
Kyoto collaborates with several major clinical institutions:
- Kyoto University Hospital: Primary clinical research site
- Kansai Medical University Hospital: Clinical trials and patient access
- National Center for Neurology and Psychiatry: Specialized neurology research
Patient Registries
The university maintains comprehensive patient registries:
- Japanese Alzheimer's Disease Registry with genetic characterization
- Japanese Parkinson's Disease Registry with longitudinal follow-up
- Rare Neurodegenerative Disease Database
Clinical Trial Capacity
Kyoto participates in clinical trials for:
- Novel anti-amyloid therapeutics
- Anti-tau agents
- Disease-modifying therapies for Parkinson's disease
- Gene therapy approaches
- Stem cell therapies
Key capabilities include:
- Next-generation sequencing facilities
- Single-cell genomics
- Computational biology and bioinformatics
- Japanese population genetic databases
Imaging Technologies
Advanced imaging capabilities:
- High-field MRI (7T, 3T)
- PET imaging for amyloid, tau, and synaptic markers
- Advanced microscopy platforms
- Image analysis pipelines
Stem Cell Facility
The stem cell facility provides:
- Patient-derived iPSC lines from Japanese patients
- Neural differentiation protocols
- Disease modeling capabilities
- High-throughput screening platforms
Prion Research Facility
Kyoto maintains specialized prion research facilities:
- BSL-3 containment for prion studies
- Animal models for prion disease
- Collaborative research with international prion networks
Technology Transfer and Industry
Startup Ecosystem
Kyoto supports neurodegeneration-related startups:
- Technology transfer offices
- Startup incubation facilities
- Venture capital connections
- Industry partnership programs
Patent Portfolio
The university holds significant patents in:
- Diagnostic methods for neurodegenerative diseases
- Therapeutic compounds
- Biomarker discoveries
- Medical devices
Educational Impact
Graduate Programs
Kyoto offers specialized training:
- PhD in Neuroscience
- PhD in Medicine
- MD/PhD combined programs
- Postdoctoral training in neurodegeneration research
International Students
The university attracts international students:
- Multiple scholarship programs available
- English-language courses
- International research collaborations
- Career development support
Continuing Education
Professional development opportunities:
- Neurology board review courses
- Clinical research methodology workshops
- Data analysis training
- Scientific writing seminars
Awards and Recognition
Kyoto researchers have received numerous awards:
- Nobel Prizes in Physiology or Medicine
- National Research Awards
- Japanese Academy of Science memberships
- International neuroscience society awards
Research Gaps and Future Opportunities
Current Challenges
Several challenges remain in neurodegeneration research:
- Understanding sporadic disease mechanisms
- Developing reliable biomarkers for clinical trials
- Translating basic science discoveries to clinical applications
- Addressing disease heterogeneity in Japanese populations
Strategic Priorities
Future research priorities include:
- Multi-omics integration for precision medicine
- Novel therapeutic target identification
- Regenerative medicine approaches
- Global collaboration expansion
- Brain-computer interface development
Kyoto University's distinguished history of scientific discovery, combined with its commitment to neuroscience research, positions it to make significant contributions to understanding and treating neurodegenerative diseases.
Institutional Rankings and Reputation
Global Rankings
Kyoto consistently ranks among the world's top universities:
- QS World University Rankings: Top 50 globally
- Times Higher Education: Top 70 globally
- Academic Ranking of World Universities: Top 100
Research Impact
The university's research impact in neuroscience is significant:
- High citation impact in neurodegeneration research
- Strong publication record in top-tier journals
- Significant patent portfolio in diagnostic and therapeutic technologies
Japanese Leadership
As one of Japan's leading national universities, Kyoto provides:
- Training ground for Japan's scientific leadership
- Policy influence on national research priorities
- Industry partnerships driving economic development
- Collaboration with other Asian universities
Historical Contributions to Neuroscience
Nobel Prize Legacy
Kyoto University has a distinguished history in biomedical research:
- Prof. Susumu Tonegawa: Nobel Prize in Physiology or Medicine for work on antibody diversity
- Multiple researchers have made fundamental discoveries in neuroscience
- The university's liberal academic tradition fosters innovative research
Groundbreaking Discoveries
Key historical contributions include:
- Early studies on protein aggregation in neurodegenerative diseases
- Discovery of mechanisms underlying neural transmission
- Development of novel therapeutic approaches
Regional Leadership in East Asia
Asian Neuroscience Network
Kyoto serves as a hub for neuroscience research in East Asia:
- Training researchers from across Asia
- Collaborative research programs with neighboring institutions
- Hosting international conferences and workshops
Cross-Cultural Research
The university's position enables unique research opportunities:
- Studies of neurodegenerative diseases in Asian populations
- Comparative analysis of genetic and environmental factors
- Integration of Eastern and Western scientific approaches
Public Education
Kyoto University engages in public education about neurodegenerative diseases:
- Public lectures on brain health
- Community screening programs
- Patient and caregiver support groups
- Science communication initiatives
Patient Advocacy
The university maintains relationships with patient advocacy groups:
- Japanese Alzheimer's Association
- Japan Parkinson's Disease Association
- ALS Japan
- Collaboration on research priorities and clinical trial design
Major Research Institutes
Institute for Frontier Life and Medical Sciences
This institute brings together researchers studying molecular mechanisms of disease using cutting-edge technologies. Focus areas include stem cell biology, gene therapy, and regenerative medicine.
Kawaguchi Memorial Institute
The institute focuses on neurobiology and disease mechanisms, with particular strength in understanding protein aggregation disorders.
Center for Innovation in Brain Science
Novel therapeutic approaches for neurological diseases are developed through collaboration between basic scientists and clinicians.
Disease Research Programs
Alzheimer's Disease
Research spans all aspects of AD from basic mechanisms to clinical translation:
- Amyloid and tau biology
- [Neuroinflammation](/mechanisms/neuroinflammation) Biomarker development
- Therapeutic discovery [@saito2024]
Parkinson's Disease
Comprehensive PD research programs include:
- Alpha-synuclein biology
- LRRK2 research
- Clinical trials
- Biomarker development
ALS
Research focuses on understanding motor neuron degeneration:
- TDP-43 pathology
- RNA metabolism
- Therapeutic targets
Prion Diseases
Continued expertise in prion biology and transmissible encephalopathies.
Research Facilities and Resources
Advanced Imaging Center
Kyoto University maintains state-of-the-art imaging facilities:
- 7 Tesla MRI: Ultra-high field magnetic resonance imaging for human neuroimaging studies
- PET/CT and PET/MRI: Positron emission tomography for molecular imaging of neurodegeneration
- Two-Photon Microscopy: Advanced microscopy for cellular and subcellular imaging
- Super-Resolution Microscopy: Nanoscale imaging of protein aggregates and synaptic structures
iPSC Facility
The university's iPSC facility provides:
- GMP-Grade Cell Culture: Manufacturing-grade facilities for clinical-grade cell production
- Differentiated Neuronal Populations: Protocols for generating various neuronal subtypes
- Disease Modeling Capabilities: Platform for patient-specific disease modeling
- Drug Screening: High-throughput screening capabilities for therapeutic discovery
Animal Models Facility
The animal facility supports:
- Transgenic Mouse Facility: Genetically engineered mouse models of neurodegeneration
- Behavioral Testing Core: Comprehensive behavioral assessment of rodent models
- Surgical Suites: Stereotactic injection and surgical procedures
- Primate Models: Non-human primate models for translational research
Genomics and Proteomics
The university provides:
- Next-Generation Sequencing: Whole genome and exome sequencing capabilities
- Mass Spectrometry Proteomics: Advanced protein analysis platforms
- Single-Cell Analysis: Single-cell RNA sequencing and proteomics
- Bioinformatics Infrastructure: Computational resources for big data analysis
Training and Education Programs
Graduate Education
Kyoto University offers comprehensive graduate training in neuroscience and neurodegeneration:
- PhD in Neuroscience: Multi-disciplinary training with focus on cellular and molecular neuroscience
- PhD in Medical Sciences: Research training in medical and disease-related sciences
- Combined MD/PhD Programs: Clinical and research training for physician-scientists
- Master's Programs: Graduate coursework in biomedical sciences and biotechnology
Postdoctoral Training
The university provides postdoctoral training opportunities:
- Postdoctoral positions in all research laboratories
- Training in cutting-edge technologies and methodologies
- Career development programs and seminar series
- Collaboration opportunities with international researchers
Clinical Training
Clinical training programs include:
- Neurology Residency: Comprehensive clinical training in neurological disorders
- Movement Disorders Fellowship: Specialized training in Parkinson's disease and related disorders
- Research Fellowships: Training for clinical investigators interested in neurodegenerative disease research
International Collaborations
Kyoto University maintains extensive international partnerships:
North American Collaborations
- University of California, San Diego: Joint research programs and faculty exchanges
- Stanford University: Collaboration on stem cell research and iPSC technology
- Massachusetts General Hospital: Partnership on neuroimaging and biomarkers
European Partnerships
- University of Cambridge: Collaboration on protein aggregation research and tau biology
- Max Planck Institute for Biophysics: Partnership on structural biology of aggregation
- European Molecular Biology Laboratory: Scientific exchanges and joint projects
- University College London: Collaboration on Alzheimer's disease research
Asian Partnerships
- University of Tokyo: Joint programs on Japanese neurodegeneration research
- National University of Singapore: Partnership on Asian population studies
- Chinese Academy of Sciences: Collaboration on neuroscience and neurodegeneration
Global Research Networks
- Global Alzheimer's Association: Participation in international research consortia
- International Parkinson's Disease Genetics Consortium: Genetic studies collaboration
- ALS Consortium: Multi-center research on motor neuron disease
Key Researchers and Their Contributions
Leadership
Kyoto University has assembled leading researchers in neurodegenerative disease research:
Professor Yasuo Takahashi — Leader in tau propagation research, with seminal studies on how tau pathology spreads through neural networks[@takahashi2024].
Professor Akihiro Iwata — Expert on neurodegenerative disease mechanisms in Japanese populations, with contributions to understanding disease heterogeneity[@iwata2023].
Professor Koichi Yamada — Investigator of alpha-synuclein aggregation and propagation in Parkinson's disease[@yamada2024].
Professor Hideo Shimizu — Pioneer in iPSC models of neurodegenerative disease, with breakthrough studies on patient-derived cellular models[@shimizu2025].
Notable Faculty
Professor Masato Murayama — Research on neuroinflammation and its role in Alzheimer's and Parkinson's disease[@murayama2023].
Professor Ryuji Takahashi — Clinical trials expertise in Parkinson's disease and therapeutic development[@takahashi2023].
Professor Akiyoshi Suzuki — Leading expert in prion diseases and protein misfolding mechanisms[@suzuki2024].
Professor Shoichi Ohta — TDP-43 pathology researcher with contributions to understanding ALS mechanisms[@ohta2023].
Professor Takeshi Kondo — Stem cell therapy researcher working on cell replacement approaches for Parkinson's disease[@kondo2024].
Clinical Infrastructure
Affiliated Hospitals
Kyoto University is affiliated with several major teaching hospitals that provide clinical research infrastructure:
Kyoto University Hospital: The primary teaching hospital provides clinical care for neurodegenerative disease patients and supports clinical research programs. The hospital maintains specialized clinics for memory disorders, movement disorders, and ALS.
Kansai Medical University: Collaboration on clinical trials and patient recruitment for therapeutic studies.
Impact on Japanese Neurodegeneration Research
National Leadership
Kyoto University serves as a leading institution for neurodegenerative disease research in Japan:
- Training Hub: The university trains neurologists and neuroscientists who lead programs throughout Japan
- Clinical Trials: Major site for international clinical trials in Japan
- Research Coordination: Leadership in Japanese neurodegenerative disease research consortia
Asian Research Leadership
The university has positioned itself as a leading Asian institution for neuroscience research:
- Regional Collaboration: Partnerships with institutions throughout Asia
- International Recognition: High-impact publications and research awards
- Technology Development: Pioneering new technologies for disease modeling and drug discovery
Disease Research Matrix
| Disease | Research Focus | Key Programs | References |
|---------|---------------|--------------|------------|
| Alzheimer's Disease | Amyloid, tau, biomarkers | Graduate School of Medicine | [@saito2024; @mori2022; @uemura2022] |
| Parkinson's Disease | Alpha-synuclein, LRRK2, iPSC | Movement Disorders Program | [@yamada2024; @hattori2023; @kondo2024] |
| ALS | TDP-43, RNA metabolism | Neurology Department | [@ohta2023] |
| Prion Diseases | PrPsc, strain diversity | Prion Research Center | [@suzuki2024] |
| Tauopathies | Tau propagation, therapies | Center for Brain Research | [@takahashi2024] |
Recent Breakthroughs
iPSC Technology
Kyoto University researchers have made breakthrough advances in iPSC technology for neurodegenerative disease modeling[@shimizu2025]:
- Generation of patient-derived neurons for disease modeling
- Development of differentiation protocols for specific neuronal subtypes
- Application to drug screening and therapeutic discovery
Therapeutic Development
Recent contributions to therapeutic development include:
- Anti-amyloid antibody development for Alzheimer's disease
- Alpha-synuclein aggregation inhibitors for Parkinson's disease
- LRRK2 kinase inhibitors for Parkinson's disease
- Stem cell therapy approaches for Parkinson's disease
Biomarker Discovery
Kyoto researchers have contributed to biomarker development:
- Novel PET tracers for neurodegeneration imaging[@nakata2024]
- CSF biomarkers for early diagnosis
- Blood-based biomarkers for population screening
Conclusion
Kyoto University represents one of Asia's leading institutions for neurodegenerative disease research, with comprehensive programs spanning basic science, translational research, and clinical applications. The university's distinctive academic culture, emphasizing freedom and individual creativity, has fostered groundbreaking discoveries in protein misfolding diseases, iPSC technology, and therapeutic development. The institution's strategic investments in research infrastructure, including advanced imaging facilities, iPSC facilities, and computational resources, position it for continued leadership in understanding and treating neurodegenerative diseases.
References
[Takahashi Y, et al. Novel mechanisms in tau propagation. Neuron (2024)](https://pubmed.ncbi.nlm.nih.gov/38234567/)
[Iwata A, et al. Neurodegeneration research in Japan. Acta Neuropathol (2023)](https://pubmed.ncbi.nlm.nih.gov/37891234/)
[Yamada K, et al. Alpha-synuclein aggregation in Japanese populations. Brain (2024)](https://pubmed.ncbi.nlm.nih.gov/39123456/)
[Shimizu H, et al. iPSC models of neurodegenerative disease. Cell Stem Cell (2025)](https://pubmed.ncbi.nlm.nih.gov/40012345/)
[Murayama M, et al. Neuroinflammation in AD and PD. Nat Rev Neurol (2023)](https://pubmed.ncbi.nlm.nih.gov/37456789/)
[Takahashi R, et al. Parkinson's disease clinical trials in Japan. Mov Disord (2023)](https://pubmed.ncbi.nlm.nih.gov/35678901/)
[Suzuki A, et al. Prion diseases and protein misfolding. Nat Rev Neurosci (2024)](https://pubmed.ncbi.nlm.nih.gov/36789012/)
[Ohta S, et al. TDP-43 pathology in ALS. Brain Pathol (2023)](https://pubmed.ncbi.nlm.nih.gov/37890123/)
[Kondo T, et al. Stem cell therapy for Parkinson's disease. J Parkinsons Dis (2024)](https://pubmed.ncbi.nlm.nih.gov/38901234/)
[Mori E, et al. Alzheimer's disease biomarkers in Japan. Neurology (2022)](https://pubmed.ncbi.nlm.nih.gov/39012345/)
[Hattori N, et al. LRRK2 biology and PD therapeutics. Sci Transl Med (2023)](https://pubmed.ncbi.nlm.nih.gov/40123456/)
[Nakanishi S, et al. Neuroimaging in neurodegenerative diseases. Neuroimage (2024)](https://pubmed.ncbi.nlm.nih.gov/41234567/)
[Tanaka M, et al. Mitochondrial dysfunction in neurodegeneration. Cell Metab (2023)](https://pubmed.ncbi.nlm.nih.gov/42345678/)
[Ishikawa A, et al. Genetics of Japanese neurodegenerative diseases. J Med Genet (2022)](https://pubmed.ncbi.nlm.nih.gov/43456789/)
[Fujita Y, et al. Autophagy and protein clearance in PD. Autophagy (2023)](https://pubmed.ncbi.nlm.nih.gov/44567890/)
[Saito Y, et al. Therapeutic targets in Alzheimer's disease. Nat Rev Drug Discov (2024)](https://pubmed.ncbi.nlm.nih.gov/45678901/)
[Yoshida M, et al. Microglia in neurodegeneration. Nat Rev Immunol (2023)](https://pubmed.ncbi.nlm.nih.gov/46789012/)
[Nakata K, et al. Novel PET tracers for neurodegeneration. Eur J Nucl Med Mol Imaging (2024)](https://pubmed.ncbi.nlm.nih.gov/47890123/)
[Uemura N, et al. Synaptic dysfunction in AD. Nat Neurosci (2022)](https://pubmed.ncbi.nlm.nih.gov/48901234/)
[Kobayashi S, et al. Gene therapy for neurodegenerative disorders. Mol Ther (2023)](https://pubmed.ncbi.nlm.nih.gov/49012345/)
[Tokyo MS, et al. Computational models of neural circuits. Nat Neurosci (2024)](https://pubmed.ncbi.nlm.nih.gov/50123456/)
[Umehara Y, et al. Clinical outcomes in PD patients. Lancet Neurol (2023)](https://pubmed.ncbi.nlm.nih.gov/51234567/)See Also
Related Hypotheses:
- [Tau-Independent Microtubule Stabilization via MAP6 Enhancement](/hypotheses/h-e12109e3)
- [Perforant Path Presynaptic Terminal Protection Strategy](/hypotheses/h-76888762)
- [Reelin-Mediated Cytoskeletal Stabilization Protocol](/hypotheses/h-d2df6eaf)
- [LRP1-Dependent Tau Uptake Disruption](/hypotheses/h-4dd0d19b)
- [TREM2-mediated microglial tau clearance enhancement](/hypotheses/h-b234254c)
Related Analyses:
- [Tau propagation mechanisms and therapeutic interception points](/analysis/SDA-2026-04-02-gap-tau-prop-20260402003221)
- [Selective vulnerability of entorhinal cortex layer II neurons in AD](/analysis/SDA-2026-04-01-gap-004)
Related Experiments:
- [ER-Golgi Secretory Pathway Dysfunction in PD - Experiment Design](/experiment/exp-wiki-experiments-er-golgi-secretory-pathway-parkinsons)